266 related articles for article (PubMed ID: 26045227)
1. Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas.
Pérez-Callejo D; González-Rincón J; Sánchez A; Provencio M; Sánchez-Beato M
Cancer Treat Rev; 2015 Sep; 41(8):680-9. PubMed ID: 26045227
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
3. [Rituximab: mechanism of action and resistance].
Dalle S; Dumontet C
Bull Cancer; 2007 Feb; 94(2):198-202. PubMed ID: 17337389
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
5. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
Czuczman MS; Olejniczak S; Gowda A; Kotowski A; Binder A; Kaur H; Knight J; Starostik P; Deans J; Hernandez-Ilizaliturri FJ
Clin Cancer Res; 2008 Mar; 14(5):1561-70. PubMed ID: 18316581
[TBL] [Abstract][Full Text] [Related]
6. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy.
Friedberg JW
Hematology Am Soc Hematol Educ Program; 2005; ():329-34. PubMed ID: 16304399
[TBL] [Abstract][Full Text] [Related]
7. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
8. Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates.
Leonard JP
Hematology Am Soc Hematol Educ Program; 2005; ():335-9. PubMed ID: 16304400
[TBL] [Abstract][Full Text] [Related]
9. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.
Zhou X; Hu W; Qin X
Oncologist; 2008 Sep; 13(9):954-66. PubMed ID: 18779537
[TBL] [Abstract][Full Text] [Related]
10. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
[TBL] [Abstract][Full Text] [Related]
11. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
Smith MR
Oncogene; 2003 Oct; 22(47):7359-68. PubMed ID: 14576843
[TBL] [Abstract][Full Text] [Related]
12. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
[TBL] [Abstract][Full Text] [Related]
13. Understanding rituximab function and resistance: implications for tailored therapy.
Amoroso A; Hafsi S; Militello L; Russo AE; Soua Z; Mazzarino MC; Stivala F; Libra M
Front Biosci (Landmark Ed); 2011 Jan; 16(2):770-82. PubMed ID: 21196202
[TBL] [Abstract][Full Text] [Related]
14. The future of anti-CD20 monoclonal antibodies: are we making progress?
Alduaij W; Illidge TM
Blood; 2011 Mar; 117(11):2993-3001. PubMed ID: 21209380
[TBL] [Abstract][Full Text] [Related]
15. Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy.
Jazirehi AR; Bonavida B
Methods Mol Biol; 2011; 731():407-19. PubMed ID: 21516425
[TBL] [Abstract][Full Text] [Related]
16. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
[TBL] [Abstract][Full Text] [Related]
17. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
Nishida M; Usuda S; Okabe M; Miyakoda H; Komatsu M; Hanaoka H; Teshigawara K; Niwa O
Int J Oncol; 2007 Jul; 31(1):29-40. PubMed ID: 17549402
[TBL] [Abstract][Full Text] [Related]
18. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
[TBL] [Abstract][Full Text] [Related]
19. Direct effect of rituximab in B-cell-derived lymphoid neoplasias: mechanism, regulation, and perspectives.
Bezombes C; Fournié JJ; Laurent G
Mol Cancer Res; 2011 Nov; 9(11):1435-42. PubMed ID: 21921050
[TBL] [Abstract][Full Text] [Related]
20. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]